Phase I study to evaluate safety and efficacy of autologous dexosomes loaded with tumor antigens (MAGE-A3, -A4, -A10, and MAGE-3DPO4), administered in 4 doses. Measurement of the immunologic responses and monitoring the clinical outcomes in 13 patients at different stages. The gene discussed is MAGEA3; the disease is neoplasm.